These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

90 related articles for article (PubMed ID: 15346569)

  • 1. New risk information on IBS drug Zelnorm.
    FDA Consum; 2004; 38(4):6. PubMed ID: 15346569
    [No Abstract]   [Full Text] [Related]  

  • 2. By the way, doctor. I have irritable bowel syndrome, with frequent bloating and constipation. My doctor prescribed a six-week course of Zelnorm, which really helped. Is it safe to take long-term?
    Robb-Nicholson C
    Harv Womens Health Watch; 2005 May; 12(9):8. PubMed ID: 16047399
    [No Abstract]   [Full Text] [Related]  

  • 3. New drug approved for irritable bowel syndrome in women.
    Mayo Clin Womens Healthsource; 2004 Feb; 8(2):3. PubMed ID: 14722489
    [No Abstract]   [Full Text] [Related]  

  • 4. Balancing drug risk and benefit: toward refining the process of FDA decisions affecting patient care.
    Schiller LR; Johnson DA
    Am J Gastroenterol; 2008 Apr; 103(4):815-9. PubMed ID: 18397418
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Tegaserod in treatment of women with irritable bowel syndrome].
    Munck LK; Ainsworth MA
    Ugeskr Laeger; 2007 Jun; 169(23):2190-2. PubMed ID: 17592683
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Managing irritable bowel syndrome without special drugs. Another IBS drug has been taken off the market because of serious side effects. Now what?
    Harv Womens Health Watch; 2007 Jun; 14(10):3-4. PubMed ID: 18018315
    [No Abstract]   [Full Text] [Related]  

  • 7. Tegaserod (Zelnorm) for irritable bowel syndrome.
    DeYoung GR
    Am Fam Physician; 2004 Jan; 69(2):363-4. PubMed ID: 14765778
    [No Abstract]   [Full Text] [Related]  

  • 8. Desperately seeking serotonin... A commentary on the withdrawal of tegaserod and the state of drug development for functional and motility disorders.
    Pasricha PJ
    Gastroenterology; 2007 Jun; 132(7):2287-90. PubMed ID: 17570201
    [No Abstract]   [Full Text] [Related]  

  • 9. Tegaserod for constipation-predominant irritable bowel syndrome.
    Kale-Pradhan PB; Wilhelm SM
    Pharmacotherapy; 2007 Feb; 27(2):267-77. PubMed ID: 17253916
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Tegaserod for female patients suffering from IBS with mixed bowel habits or constipation: a randomized controlled trial.
    Chey WD; Paré P; Viegas A; Ligozio G; Shetzline MA
    Am J Gastroenterol; 2008 May; 103(5):1217-25. PubMed ID: 18477346
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Safer alternatives to Zelnorm.
    Consum Rep; 2004 Sep; 69(9):47. PubMed ID: 15305425
    [No Abstract]   [Full Text] [Related]  

  • 12. New drug for women with irritable bowel syndrome.
    Mayo Clin Health Lett; 2003 Dec; 21(12):4. PubMed ID: 14971349
    [No Abstract]   [Full Text] [Related]  

  • 13. Effect of tegaserod on colonic transit time in male patients with constipation-predominant irritable bowel syndrome.
    Harish K; Hazeena K; Thomas V; Kumar S; Jose T; Narayanan P
    J Gastroenterol Hepatol; 2007 Aug; 22(8):1183-9. PubMed ID: 17688659
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The FDA's decision-making process: isn't it time to temper the principle of protective paternalism?
    Brandt LJ
    Am J Gastroenterol; 2008 May; 103(5):1226-7. PubMed ID: 18477347
    [TBL] [Abstract][Full Text] [Related]  

  • 15. FDA approves one drug for irritable bowel syndrome but suspends another.
    Harv Womens Health Watch; 2008 Aug; 15(12):7. PubMed ID: 19115501
    [No Abstract]   [Full Text] [Related]  

  • 16. Tegaserod in the treatment of constipation-predominant irritable bowel syndrome. Do the risks outweigh the benefits?
    Wood P
    Naunyn Schmiedebergs Arch Pharmacol; 2012 Jan; 385(1):1-3. PubMed ID: 21969099
    [No Abstract]   [Full Text] [Related]  

  • 17. Review article: the safety profile of tegaserod.
    Schoenfeld P
    Aliment Pharmacol Ther; 2004 Nov; 20 Suppl 7():25-30. PubMed ID: 15521852
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Tegaserod in patients with irritable bowel syndrome.
    Schooff M; Stelter C
    Am Fam Physician; 2004 Dec; 70(11):2107-8. PubMed ID: 15606056
    [No Abstract]   [Full Text] [Related]  

  • 19. Symptomatic efficacy of beidellitic montmorillonite in irritable bowel syndrome: a randomized, controlled trial.
    Ducrotte P; Dapoigny M; Bonaz B; Siproudhis L
    Aliment Pharmacol Ther; 2005 Feb; 21(4):435-44. PubMed ID: 15709995
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Drug evaluation: Pumosetrag for the treatment of irritable bowel syndrome and gastroesophageal reflux disease.
    Evangelista S
    Curr Opin Investig Drugs; 2007 May; 8(5):416-22. PubMed ID: 17520871
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.